Abstract 629
Aim/Background
This study investigates the frequency, impact of KRAS mutation and the association between clinicopathological features and KRAS status in CRC Saudi patients.
Methods
We retrospectively studied tumor samples of 221 Saudi CRC patients for KRAS status, clinicopathological characteristics and clinical outcome.
Results
KRAS mutations were identified in 97/221 (45%) tumors. Gender, smoking history, stage at diagnosis, differentiation and lymphatic and vascular invasion were tested as potential risk predictors for KRAS status. Only gender was found to be a potential risk factor. Female compared to male gender posed a higher significant chance of mutant status (59%, P = 0.027). KRAS status did not significantly impact on clinical outcome and overall survival (OS) (median OS was not reached in both groups (P = 0.87).
Conclusions
This retrospective study highlights the incidence of KRAS mutations among Saudi population with CRC (45%). It is more frequently seen in female than male. This higher incidence could be attributed to ethnic differences and warrant further investigation to clarify the effect of other environmental and genetic factors. However in these patients, KRAS mutation status did not significantly impact clinical outcome or overall survival.
Clinical trial identification
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
Vitamin D3 (cholecalciferol) acts as a negative regulator of breast cancer cell invasiveness in the absence of activation of classical VDR signalling
Presenter: MD Musharraf Hossain
Session: Poster presentation 1
Resources:
Abstract
VCP/p97 inhibition is a therapeutic strategy to overcome drug resistance in ovarian and pancreatic cancers
Presenter: Yuliana Astuti
Session: Poster presentation 1
Resources:
Abstract
Upregulation of the interleukin 17/granulocyte-colony stimulating factor/fibroblast growth factor axis and its correlation with indoleamine 2,3-dioxygenase in breast cancer
Presenter: Kosuke Kawaguchi
Session: Poster presentation 1
Resources:
Abstract
Updated analysis: Phase II trial of irinotecan plus S-1 (IRIS) with cetuximab (IRIS/Cet) in pre-treated patients with KRAS wild type metastatic colorectal cancer (mCRC): HGCSG0902
Presenter: Ayumu Hosokawa
Session: Poster presentation 1
Resources:
Abstract
Updated analysis: observational cohort study of 1st line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Comparison of infusional FU/oxaliplatin (OX) + BV and oral FU/OX + BV
Presenter: Yoshito Komatsu
Session: Poster presentation 1
Resources:
Abstract
Tuberculosis exposure and the risk of cancer
Presenter: Vincent Yi-Fong Su
Session: Poster presentation 1
Resources:
Abstract
Triple negative breast cancer and androgen receptor expression: a forerunner for a novel hormonal approach
Presenter: Prameela Chelakkot G
Session: Poster presentation 1
Resources:
Abstract
Treatment of radiation induced side-effects in prostate cancer patients with hyperbaric oxygen therapy
Presenter: HAYATO Takeda
Session: Poster presentation 1
Resources:
Abstract
Tolerability and efficacy of neoadjuvant chemotherapy with three-weekly interval methotrexate, doxorubicin, vinblastine and cisplatin regimen for patients with locally advanced bladder cancer
Presenter: Satoko Arai
Session: Poster presentation 1
Resources:
Abstract
To compare the efficacy and safety of pazopanib and sunitinib in metastatic renal cell carcinoma (RCC) of Chinese population
Presenter: Michelle Fong Ting Chan
Session: Poster presentation 1
Resources:
Abstract